title: New Therapies for Psoriasis.
abstract: The anti-tumor necrosis factor (TNF)-α agents represent the second generation of psoriasis therapy. Research has produced a third generation of biologic treatments, some of which offer greater efficacy than the TNF-α inhibitors. This article reviews the data documenting the efficacy and safety of three types of biologics.
authors.affiliation: Clinical Professor of Dermatology Saint Louis University Central Dermatology St Louis, Missouri.
authors.forename: Craig L
authors.initials: CL
authors.lastname: Leonardi
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003880:Dermatology / Q000639:trends*; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D013792:Thalidomide; C555450:secukinumab; C505730:apremilast
keywords: IL-12/23 inhibitors; IL-17/IL-17A inhibitors; IL-23 inhibitors